Metabolic Diseases  >>  Suglat (ipragliflozin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
NCT01242215: A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Checkmark P3 data
Nov 2012 - Nov 2012: P3 data
Completed
3
243
Japan
ipragliflozin, ASP1941, Placebo, Sulfonylurea, Glibenclamide, Gliclazide, Glimepiride
Astellas Pharma Inc
Type 2 Diabetes Mellitus
04/12
04/12
NCT01242228: A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Completed
3
106
Japan
ipragliflozin, ASP1941, DPP-4 inhibitor, saxagliptin, alogliptin, sitagliptin, vildagliptin
Astellas Pharma Inc
Type 2 Diabetes Mellitus
06/12
06/12
NCT01316107: A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Completed
3
122
Japan
ipragliflozin, ASP1941, nateglinide, Starsis, Fastic
Astellas Pharma Inc
Type 2 Diabetes Mellitus
10/12
10/12
NCT01514838: A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus

Terminated
3
46
RoW
ASP1941, ipragliflozin, acarbose, Placebo
Astellas Pharma Inc
Type II Diabetes Mellitus
10/12
10/12
NCT01316094: A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment

Completed
3
165
Japan
ASP1941, placebo
Astellas Pharma Inc
Type 2 Diabetes Mellitus
11/12
11/12
NCT01505426: A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients

Completed
3
171
RoW
ASP1941, ipragliflozin, metformin, Placebo
Astellas Pharma Inc
Type II Diabetes Mellitus
01/13
01/13

Download Options